ibezapolstat

Ibezapolstat is a novel, orally administered small molecule antibiotic developed as a Gram-positive selective spectrum (GPSS) antibacterial. It is the first of a new class of DNA polymerase IIIC inhibitors, targeting an enzyme essential for replication in low G+C content Gram-positive bacteria such as Clostridioides difficile. This mechanism provides selective activity against C. difficile while sparing other beneficial gut microbiota, including Actinobacteria and Bacteroidetes species. Ibezapolstat has demonstrated potent in vitro and clinical efficacy against C. difficile infection (CDI), including multidrug-resistant strains, with minimal disruption to the gut microbiome and favorable safety profiles in Phase 1 and Phase 2 trials. The drug is being advanced to Phase 3 clinical development for CDI treatment[1][3][5][6][7].

Other names

ibezapolstatIbezapolstat [USAN]